drugset / Trial / NCT00268892
Extension Study Investigating the Long-Term Safety of Degarelix Three-Month Depots in Patients With Prostate Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this extension study was to collect long-term safety and tolerability information to support a marketing authorisation application for a three-month dosage regimen of degarelix.
Timeline
- Start
- 2006-01
- Primary completion
- 2009-09
- Completion
- 2009-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Degarelix | Other / unclassified | 360 mg | Subcutaneous |
| Subject | Degarelix | Other / unclassified | 480 mg | Subcutaneous |